Chen Wei-Jen, Shen Siou-Ru, Hsu Wei-Hsuan, Lee Bao-Hong, Wei Yu-Shan, Chu Hui-Fang, Tseng Ming-Chung, Shen Tang-Long
Research and Development Department, Syngen Biotech Co., Ltd., Tainan, Taiwan.
Graduate Institute of Management, Minghsin University of Science and Technology, Hsinchu, Taiwan.
J Food Drug Anal. 2025 Mar 31;33(1):61-74. doi: 10.38212/2224-6614.3535.
5-Fluorouracil (5-FU) disrupts intestinal cells and causes dysbiosis in the gut microbiota. This study explores the potential of Bacillus coagulans-198 (BC198) to mitigate gut microbiota imbalance and mucositis caused by 5-fluorouracil. L-glutamine is used to alleviate mucositis, and this study found that BC198 exhibits protective effects on the gut, including maintaining a healthy microbiota and reducing intestinal inflammation, regardless of whether L-glutamine is used in combination. Therefore, it can help reduce the deterioration of the gut environment caused by 5-fluorouracil. BC198 can be provided to cancer patients to prevent severe side effects, thereby improving their treatment outcomes and nutritional status.
5-氟尿嘧啶(5-FU)会破坏肠道细胞并导致肠道微生物群失调。本研究探讨凝结芽孢杆菌-198(BC198)减轻5-氟尿嘧啶引起的肠道微生物群失衡和粘膜炎的潜力。L-谷氨酰胺用于减轻粘膜炎,本研究发现,无论是否联合使用L-谷氨酰胺,BC198对肠道均具有保护作用,包括维持健康的微生物群和减轻肠道炎症。因此,它有助于减少5-氟尿嘧啶引起的肠道环境恶化。可将BC198提供给癌症患者以预防严重的副作用,从而改善其治疗效果和营养状况。